/

BOLD

Boundless Bio, Inc.After hours

2.39−0.04 −1.65%USD

NasdaqGS · as of Oct 14, 16:00 ET · 15m delay

Open

2.43

Prev close

2.43

Day range

2.392.49

52-week range

0.96103.16

Volume

129.81K0.73×

Mkt cap

55.23M

P/E ttm

—

Fwd P/E

-2.44

EPS ttm

-2.85

Div yield

0.00%

Earnings

—

From 52w high

−24.46%

Price Chart

Yahoo Finance · delayed

BOLDOct 14, 2026O 2.43H 2.48L 2.38C 2.39−0.04 (−1.65%)Vol 129.81K

SMA 502.76
SMA 2001.84

1Y change +83.85% since Oct 13, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

BOLD Boundless Bio, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −9.47%
1 month: −15.85%
3 months: −3.24%
6 months: +46.63%
Year to date: +99.17%
1 year: +81.06%

Valuation & ownership

Market cap: 55.23M
Enterprise value: −17.35M
P/E (ttm): —
Forward P/E: -2.44
PEG ratio: —
Price / book: 0.81
Price / sales (ttm): —
EV / EBITDA: 0.27
EPS (ttm): -2.85
EPS (forward): -0.9800
Beta (5y monthly): 0.47
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 23.11M
Float: 16.08M
Short % of float: 5.52%
Short ratio (days): 5.97
Held by insiders: 12.53%
Held by institutions: 67.26%
Avg volume (3m): 176.89K
50-day average: 2.77
200-day average: 1.84
52-week change: +81.06%
S&P 500 52-week: +17.00%

Technicals (daily)

RSI (14): 31.1
vs 50-day SMA: −13.46%
vs 200-day SMA: +29.75%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.55%
Realised vol (20d, ann.): 39.7%
From 52-week high: −24.46%
From 52-week low: +148.70%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

4.00

+67.36% implied

Low 4.00Median 4.00High 4.00

Recommendation trend

Now0 / 1 / 0
1m ago0 / 1 / 0

Buy / hold / sell counts

DES

About Boundless Bio, Inc.

Yahoo Finance profile

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype. The company was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. Boundless Bio, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 28
Headquarters: San Diego, CA, United States
Website: boundlessbio.com
Officers: Ms. Jessica Oien J.D. President, Principal Executive Officer, Chief Legal Officer & Corporate Secretary
Mr. David Hinkle Senior VP of Finance, Controller & Corporate Treasurer
Ms. Meredith Wesley Chief Human Resources Officer

SEAS

Seasonality · BOLD

2024–2026 · monthly returns

Strongest month Jul +8.40%Weakest month Jun −32.87%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.3	0.0	-5.2	32.7	-0.7	72.4	0.0	12.4	-10.7	-4.8			+99.2%
2025	-21.0	-15.7	-21.8	16.6	-37.5	-8.2	17.3	-5.5	9.8	13.8	-16.4	2.6	−58.6%
2024				-30.5	-7.9	-57.6	-0.5	-6.0	-4.1	-15.9	-6.5	6.2	−79.6%

INSD

Insider Activity · BOLD

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

627.4K shares

Sells, 6 months

34.3K shares

Net shares

+593.1K

Net change in insider shares

+26.30%

Date	Insider	Transaction	Shares	Value
Aug 25, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Sale at price 2.97 per share.	18.3K	$54.35K
Jul 20, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.44 per share.	4.9K	$11.87K
Jul 15, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.43 - 2.44 per share.	64K	$155.65K
Jul 12, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.42 - 2.48 per share.	91.6K	$222.07K
Jul 7, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.46 - 2.49 per share.	57.2K	$141.87K
Jul 1, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.49 - 2.54 per share.	107.5K	$268.88K
Jun 30, 2026	Arch Venture Fund Ix, L.P.Beneficial Owner of more than 10% of a Class of Security	Sale at price 2.49 per share.	16K	$39.84K
Jun 30, 2026	Arch Venture Fund Ix, L.P.Beneficial Owner of more than 10% of a Class of Security	Conversion of Exercise of derivative security at price 1.03 per share.	16K	$16.48K
Jun 28, 2026	Tang Kevin CBeneficial Owner of more than 10% of a Class of Security	Purchase at price 2.47 - 2.56 per share.	286.3K	$714.77K

13F

Investors Holding BOLD

latest 13F filings of 29 followed managers

Investors holding BOLD
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$1.2M	0.00%	471.57K	+18%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

BOLD

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

BOLD

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Boundless Bio, Inc.

Seasonality · BOLD

Insider Activity · BOLD

Congress Trades · BOLD

Investors Holding BOLD

Investors Holding BOLD

Congress Trades · BOLD

Insider Activity · BOLD

Seasonality · BOLD

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Boundless Bio, Inc.

Financial Snapshot

Earnings & Dividends

News